Author(s):
Sanchita J. Borate, Laxmikat M. Puran, Mansi G. Gujare, Sunita A. Wanjale, Anjum H. Khan
Email(s):
sanchita18borate@gmail.com
DOI:
10.52711/2231-5713.2026.00039 
Address:
Sanchita J. Borate, Laxmikat M. Puran, Mansi G. Gujare, Sunita A. Wanjale, Anjum H. Khan
Department of Pharmacology, Yashoda Technical Campus, DBATU University, Satara 415015, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 3,
Year - 2026
ABSTRACT:
Infertility is a major issue in women's reproductive health, prompting the development of novel therapeutic approaches. Advances in pharmacological interventions, such as clomiphene citrate, gonadotropins, Human chorionic gonadotropin (HCG), follicular stimulating hormones (FSH), Selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIS), and luteinizing hormone, have improved ovulatory function and pregnancy rates. In addition, specific pharmacological therapy, such as metformin for polycystic ovarian syndrome (PCOS) and progesterone for luteal phase support, Antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and dopamine agonists have important roles in fertility augmentation. Antioxidants such as Coenzyme Q10 (CoQ10), Vitamin D, and N-acetyl cysteine (NAC), carotenoids, omega-3 fatty acids, vitamins C and E, myoinositol, and carnitines acids all serve to reduce oxidative stress. Probiotics modulate the gut and vaginal microbiota and increasing in acceptance, with certain strains such as Lactobacillus crispatus and Lactobacillus rhamnosus indicating potential for enhancing reproductive results. However, these developments raise ethical considerations, provide regulatory obstacles, and pose possible hazards that must be investigated further. This study focuses on the varied terrain of fertility enhancement techniques, including pharmaceutical, dietary, regenerative, and technological approaches. Future research should concentrate on individualized reproductive care, which addresses individual patient needs and maximizes therapy efficacy.
Cite this article:
Sanchita J. Borate, Laxmikat M. Puran, Mansi G. Gujare, Sunita A. Wanjale, Anjum H. Khan. Restoring Reproductive Potential: A Broad-Spectrum Review of Hormonal, Nutritional and Antioxidant Therapies in Infertility. Asian Journal of Pharmacy and Technology. 2026; 16(3):271-1. doi: 10.52711/2231-5713.2026.00039
Cite(Electronic):
Sanchita J. Borate, Laxmikat M. Puran, Mansi G. Gujare, Sunita A. Wanjale, Anjum H. Khan. Restoring Reproductive Potential: A Broad-Spectrum Review of Hormonal, Nutritional and Antioxidant Therapies in Infertility. Asian Journal of Pharmacy and Technology. 2026; 16(3):271-1. doi: 10.52711/2231-5713.2026.00039 Available on: https://ajptonline.com/AbstractView.aspx?PID=2026-16-3-9
REFERENCES:
1. Vitagliano A, Petre GC, Francini-Pesenti F, et al. Dietary supplements for female infertility: a critical review of their composition. Nutrients. 2021; 13(10): 3552. doi:10.3390/nu13103552.
2. Zegers-Hochschild F, Adamson GD, Dyer S, et al. The international glossary on infertility and fertility care, 2017. Hum Reprod. 2017; 32(1): 1786-1801.
3. Vander Borght M, Wyns C. Fertility and infertility: definition and epidemiology. Clin Biochem. 2018; 62: 2-10. doi: 10.1016/j.clinbiochem.2018.03.012.
4. Hamada AJ, Montgomery B, Agarwal A. Male infertility: a critical review of pharmacologic management. Expert Opin Pharmacother. 2012; 13(17): 2511-2531.
5. Tournaye H, Krausz C, Oates RD. Novel concepts in the aetiology of male reproductive impairment. Lancet Diabetes Endocrinol. 2017; 5(7): 544-553.
6. Zegers-Hochschild F, Adamson GD, Dyer S, Racowsky C, de Mouzon J, Sokol R, et al. The international glossary on infertility and fertility care, 2017. Hum Reprod. 2017; 32(9): 1786-1801. doi:10.1093/humrep/dex234.
7. Rooney KL, Domar AD. The relationship between stress and infertility. Dialogues Clin Neurosci. 2018; 20(1): 41-47. doi:10.31887/DCNS.2018.20.1/klrooney.
8. Awoke MA, Wycherley TP, Earnest A, Skouteris H, Moran LJ. Profiling diet and physical activity in reproductive-age women and association with body mass index. Nutrients. 2022; 14(13): 2607. doi:10.3390/nu14132607.
9. Alesi S, Habibi N, Silva TR, et al. Influence of preconception diet on female fertility: a systematic scoping review. Hum Reprod Update. 2023; 29(6): 811-828. doi:10.1093/humupd/dmad018.
10. Schaefer E, Nock D. Impact of preconceptional multiple-micronutrient supplementation on female fertility. Clin Med Insights Womens Health. 2019; 12: 1179562X19843868. doi:10.1177/1179562X19843868.
11. Shoshany O, Abhyankar N, Mufarreh N, et al. Outcomes of anastrozole in oligozoospermic hypoandrogenic subfertile men. Fertil Steril. 2017;107(3):589-594.
12. Tadros NN, Sabanegh ES. Empiric medical therapy with hormonal agents for idiopathic male infertility. Indian J Urol. 2017; 33(3): 194-198.
13. Cole PA, Robinson CH. Mechanism and inhibition of cytochrome P-450 aromatase. J Med Chem. 1990; 33(11): 2933-2942. doi:10.1021/jm00173a001.
14. Lønning PE. Aromatase inhibition for breast cancer treatment. Acta Oncol. 1996; 35(Suppl 5): 38-43. doi:10.3109/02841869609083966.
15. Nabieva N, Fehm T, Häberle L, de Waal J, Rezai M, Baier B, et al. Influence of side effects on early therapy persistence with letrozole in postmenopausal breast cancer patients. Eur J Cancer. 2018; 96: 82-90. doi: 10.1016/j.ejca.2018.03.020.
16. Holzer H, Casper R, Tulandi T. A new era in ovulation induction. Fertil Steril. 2006; 85(2): 277-284. doi: 10.1016/j.fertnstert.2005.05.078.
17. Brown J, Farquhar C, Beck J, Boothroyd C, Hughes E. Clomiphene and anti-oestrogens for ovulation induction in PCOS. Cochrane Database Syst Rev. 2009; 4: CD002249. doi: 10.1002/14651858.CD002249.pub4.
18. De Paula Guedes Neto E, Savaris RF, von Eye Corleta H, de Moraes GS, do Amaral Cristovam R, Lessey BA. Raloxifene versus clomiphene citrate for ovulation induction in PCOS. Fertil Steril. 2011; 96(3): 769-773. doi: 10.1016/j.fertnstert.2011.06.067.
19. Feng TB. The effects of clomiphene citrate on ovarian function in rats [dissertation]. Vancouver: University of British Columbia; 1990.
20. Yilmaz S, Ünal F, Yilmaz E, Yüzbaşioğlu D, Erkal İlhan S. Evaluation of the genotoxicity of clomiphene citrate. Mutat Res Genet Toxicol Environ Mutagen. 2014; 759: 21-27. doi: 10.1016/j.mrgentox.2013.07.014.
21. Helo S, Wynia B, McCullough A. Modulation of estrogen receptor function with selective modulators: clinical implications in urology. Sex Med Rev. 2017; 5(3): 365-386.
22. Patankar SS, Kaore SB, Sawane MV, et al. Effect of clomiphene citrate on sperm density in male partners of infertile couples. Indian J Physiol Pharmacol. 2007; 51(2): 195-198.
23. Ko EY, Siddiqi K, Brannigan RE, et al. Empirical medical therapy for idiopathic male infertility: survey of AUA members. J Urol. 2012; 187(3): 973-978.
24. Schlegel PN. Aromatase inhibitors for male infertility. Fertil Steril. 2012; 98(6): 1359-1362.
25. Siddiq FM, Sigman M. Medical management of infertility. Urol Clin North Am. 2002; 29(4): 949-963.
26. de Kretser DM, Loveland KL, Meinhardt A, et al. Spermatogenesis. Hum Reprod. 1998; 13(Suppl 1): 1–8.
27. Sluka P, O’Donnell L, Bartles JR, et al. FSH regulates the formation of adherens junctions and ectoplasmic specializations between rat Sertoli cells in vitro and in vivo. J Endocrinol. 2006; 189(2): 381–395.
28. Dimitriadis F, Tsiampali C, Chaliasos N, et al. The Sertoli cell as the orchestra conductor of spermatogenesis: spermatogenic cells dance to the tune of testosterone. Hormones (Athens). 2015;14(4): 479–503.
29. Garolla A, Ghezzi M, Cosci I, et al. FSH treatment in infertile males candidate to assisted reproduction improves sperm DNA fragmentation and pregnancy rate. Endocrine. 2017; 56(2): 416–425.
30. Casamonti E, Vinci S, Serra E, et al. Short-term FSH treatment and sperm maturation: a prospective study in idiopathic infertile men. Andrology. 2017; 5(3): 414–422.
31. Barbotin AL, Ballot C, Sigala J, et al. Pregnancy after intracytoplasmic sperm injection following extended sperm preparation and hormone therapy in an azoospermic man with maturation arrest and microlithiasis: a case report and literature review. Andrologia. 2017; 49(10): e12716.
32. Cocci A, Cito G, Russo GI, et al. Effectiveness of highly purified urofollitropin treatment in patients with idiopathic azoospermia before testicular sperm extraction. Urologia. 2018; 85(1): 19–21.
33. Tarlatzis B, Tavmergen E, Szamatowicz M, Barash A, Amit A, Levitas E, et al. Use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind randomized prospective study. Hum Reprod. 2006; 21(1): 90–94. doi:10.1093/humrep/dei293.
34. Turner D, Turner EA, Aparicio NJ, et al. Response of luteinizing hormone and follicle-stimulating hormone to different doses of D-leucine-6-LH-RH ethylamide in oligospermic patients. Fertil Steril. 1976; 27: 545–548.
35. Chehval MJ, Mehan DJ. Chorionic gonadotropins in the treatment of the subfertile male. Fertil Steril. 1979; 31: 666–668.
36. Alexandre C. Study of 13 cases of ostensibly idiopathic male infertility treated successfully by HMG/HCG combination. Sem Hôp. 1978; 54: 633–636.
37. Pescosolido D, Curatola A, Gentili S, et al. A new gonadotropin treatment for idiopathic moderate oligoasthenospermia. Acta Eur Fertil. 1985;16: 129–132.
38. Iacono F, Barra S, Montano L, et al. Value of high-dose pure FSH in the treatment of idiopathic male infertility. J Urol. 1996; 102: 81–84.
39. Foresta C, Bettella A, Merico M, et al. Use of recombinant human follicle-stimulating hormone in the treatment of male factor infertility. Fertil Steril. 2002; 77(2): 238–244.
40. Santi D, Simoni M. Biosimilar recombinant follicle-stimulating hormones in infertility treatment. Expert Opin Biol Ther. 2014; 14(10): 1399–1409.
41. Chehab M, Madala A, Trussell JC. On-label and off-label drugs used in the treatment of male infertility. Fertil Steril. 2015; 103(3): 595–604.
42. Li X, Li L, Wang D, Zhang J, Yi K, Su Y, et al. Fabrication of polymeric microspheres for biomedical applications. Mater Horiz. 2024; 11(12): 2820–2855. doi:10.1039/d3mh01641b.
43. Oladghaffari M, Rahnemayan S, Tohid Z, Montazer M, Dabiri F. Incretin-based therapies and risk of breast cancer in women with type 2 diabetes mellitus: a systematic review and meta-analysis. Int J Drug Res Clin Stud. 2023; 1(1): e19. doi:10.34172/ijdrc.2023.e19.
44. Saltzstein D, Shore ND, Moul JW, Chu F, Concepcion R, de la Motte S, et al. Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects. Ther Adv Urol. 2018; 10(2): 43–50. doi:10.1177/1756287217738150.
45. Shaanxi BLOOM Tech Co. Ltd. What is leuprorelin acetate? 2024. Available from: https://www.bloomtechz.com/info/what-is-leuprorelin-acetate-95570713.html
46. Mathias JR, Clench MH, Reeves-Darby VG, Fox LM, Hsu PH, Roberts PH, et al. Effect of leuprolide acetate in patients with moderate to severe functional bowel disease: a double-blind placebo-controlled study. Dig Dis Sci. 1994; 39(6): 1155–1162. doi:10.1007/BF02093778.
47. Shore ND, Guerrero S, Sanahuja RM, Gambús G, Parente A. A new sustained-release 3-month leuprolide acetate formulation achieves and maintains castrate testosterone levels in patients with prostate cancer. Clin Ther. 2019; 41(3): 412–425. doi:10.1016/j.clinthera.2019.01.004.
48. Mezo G. Peptide and protein-based pharmaceuticals. In: Farkas E, Ryadnov M, editors. Amino acids, peptides and proteins. Vol 38. Cambridge: Royal Society of Chemistry; 2013. p. 203–252. doi:10.1039/9781849737081-00203.
49. Howles CM, Shoham Z. Drugs used for ovarian stimulation: clomiphene citrate, aromatase inhibitors, metformin, GnRH analogues, and gonadotropins. In: Textbook of assisted reproductive techniques. Boca Raton: CRC Press; 2023. p. 419–442.
50. Suh J, Lee E, Hwang S, Yoon S, Yoon BK, Bae D, et al. Dose of GnRH agonist (nafarelin acetate) affects intrafollicular PAPP-A expression in controlled ovarian hyperstimulation cycle. Eur J Obstet Gynecol Reprod Biol. 2004; 112(1): 65–68. doi:10.1016/S0301-2115(03)00317-8.
51. Evans J. Hyperglycosylated hCG: a unique human implantation and invasion factor. Am J Reprod Immunol. 2016; 75(3): 333–340. doi:10.1111/aji.12459.
52. Asch RH, Li HP, Yovich JL, Katayama KP, Balmaceda JP, Rojas FJ, et al. Failed oocyte retrieval after lack of human chorionic gonadotropin administration in assisted reproductive technology. Fertil Steril. 1992; 58(2): 361–365. doi:10.1016/S0015-0282(16)55227-3.
53. Adamopoulos DA, Pappa A, Billa E, et al. Effectiveness of combined tamoxifen citrate and testosterone undecanoate treatment in men with idiopathic oligozoospermia. Fertil Steril. 2003; 80(4): 914–920.
54. Adamopoulos DA, Nicopoulou S, Kapolla N, et al. Combination of testosterone undecanoate with tamoxifen citrate enhances seminal parameters in men with idiopathic oligozoospermia. Fertil Steril. 1997; 67(4): 756–762.
55. Ghanem H, Shaeer O, El-Segini A. Combination clomiphene citrate and antioxidant therapy for idiopathic male infertility: a randomized controlled trial. Fertil Steril. 2010; 93(7): 2232–2235.
56. Bhardwaj JK, Panchal H, Saraf P. Ameliorating effects of natural antioxidant compounds on female infertility: a review. Reprod Sci. 2020; 27: 1227–1256. doi:10.1007/s43032-020-00312-5.
57. Sikka SC, Rajasekaran M, Hellstrom WJG. Role of oxidative stress and antioxidants in male infertility. J Androl. 1995; 16(6): 464–468.
58. Aitken J, Fisher H. Reactive oxygen species generation and human spermatozoa: the balance of benefit and risk. BioEssays. 1994; 16(4): 259–267. doi:10.1002/bies.950160409.
59. Tremellen K. Oxidative stress and male infertility: a clinical perspective. Hum Reprod Update. 2008; 14(3): 243–258. doi:10.1093/humupd/dmn004.
60. Agarwal A, Gupta S, Sekhon L, Shah R. Redox considerations in female reproductive function and assisted reproduction: from molecular mechanisms to health implications. Antioxid Redox Signal. 2008; 10(8): 1375–1403. doi:10.1089/ars.2007.1964.
61. Vašková J, Klepcová Z, Špaková I, Urdzík P, Štofilová J, Bertková I, Kľoc M, Rabajdová M. Importance of natural antioxidants in female reproduction. Antioxidants (Basel). 2023; 12(4): 907. doi:10.3390/antiox12040907.
62. Mirończuk-Chodakowska I, Witkowska AM, Zujko ME. Endogenous non-enzymatic antioxidants in the human body. Adv Med Sci. 2018; 63(1): 68–78. doi:10.1016/j.advms.2017.05.005.
63. Gupta S, Agarwal A, Banerjee J, Alvarez JG. Role of oxidative stress in spontaneous abortion and recurrent pregnancy loss: a systematic review. Obstet Gynecol Surv. 2007; 62(5): 335–347. doi:10.1097/01.ogx.0000261644.89300.df.
64. Ng CM, Blackman MR, Wang C, et al. Role of carnitine in the male reproductive system. Ann N Y Acad Sci. 2004; 1033: 177–188.
65. Mongioi L, Calogero AE, Vicari E, et al. Role of carnitine in male infertility. Andrology. 2016; 4: 800–807.
66. Cooper TG, Weidner W, Nieschlag E. Influence of inflammation of the human male genital tract on secretion of seminal markers. Int J Androl. 1990; 13: 329–336.
67. Vicari E, Rubino C, De Palma A, et al. Antioxidant therapeutic efficiency after carnitine treatment in infertile patients with prostato-vesiculo-epididymitis. Arch Ital Urol Androl. 2001; 73: 15–25.
68. Vicari E, Calogero AE. Effects of treatment with carnitines in infertile patients with prostato-vesiculo-epididymitis. Hum Reprod. 2001; 16: 2338–2342.
69. Vicari E, La Vignera S, Calogero AE. Antioxidant treatment with carnitines in infertile patients with prostato-vesiculo-epididymitis and elevated seminal leukocytes. Fertil Steril. 2002; 78: 1203–1208.
70. Banihani S, Agarwal A, Sharma R, et al. Cryoprotective effect of L-carnitine on motility, vitality and DNA oxidation of human spermatozoa. Andrologia. 2014; 46: 637–641.
71. Gvozdjáková A, Kucharská J, Dubravicky J, et al. Coenzyme Q10, α-tocopherol and oxidative stress as metabolic biomarkers of male infertility. Dis Markers. 2015; 2015: 827941.
72. Alleva R, Scararmucci A, Mantero F, et al. Protective role of ubiquinol-10 against lipid hydroperoxide formation in human seminal fluid. Mol Aspects Med. 1997; 18(Suppl): S221–S228.
73. Giacone F, Condorelli RA, Mongioì LM, et al. In vitro effects of zinc, D-aspartic acid and coenzyme Q10 on sperm function. Endocrine. 2017; 56: 408–415.
74. Balercia G, Buldreghini E, Vignini A, et al. Coenzyme Q10 treatment in men with idiopathic asthenozoospermia: a placebo-controlled double-blind randomized trial. Fertil Steril. 2009; 91: 1785–1792.
75. Safarinejad MR. Efficacy of coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men. J Urol. 2009; 182: 237–248.
76. Nadjarzadeh A, Shidfar F, Amirjannati N, et al. Effect of coenzyme Q10 supplementation on antioxidant enzyme activity and oxidative stress of seminal plasma: a double-blind randomized clinical trial. Andrologia. 2014; 46: 177–183.
77. Safarinejad MR. Effect of coenzyme Q10 supplementation on partner pregnancy rate in infertile men with idiopathic oligoasthenoteratozoospermia: an open-label prospective study. Int Urol Nephrol. 2012; 44: 689–700.
78. Nadjarzadeh A, Sadeghi MR, Amirjannati N, et al. Coenzyme Q10 improves seminal oxidative defense but does not affect semen parameters in idiopathic oligoasthenoteratozoospermia: a randomized double-blind placebo-controlled trial. J Endocrinol Invest. 2011; 34: e224–e228.
79. Lafuente R, González-Comadrán M, Solà I, et al. Coenzyme Q10 and male infertility: a meta-analysis. J Assist Reprod Genet. 2013; 30: 1147–1156.
80. Condorelli RA, La Vignera S, Mongioì LM, et al. Myo-inositol as a male fertility molecule: speed them up! Eur Rev Med Pharmacol Sci. 2017; 21: 30–35.
81. Calogero AE, Condorelli RA, Russo GI, et al. Conservative nonhormonal options for the treatment of male infertility: antibiotics, anti-inflammatory drugs, and antioxidants. Biomed Res Int. 2017; 2017: 4650182.
82. Yeung CH, Anapolski M, Setiawan I, et al. Effects of putative epididymal osmolytes on sperm volume regulation of fertile and infertile c-ros transgenic mice. J Androl. 2004; 25: 216–223.
83. Bahat A, Eisenbach M. Human sperm thermotaxis is mediated by phospholipase C and inositol trisphosphate receptor Ca²⁺ channel. Biol Reprod. 2010;82:606–616.
84. Ho HC, Suarez SS. Characterization of the intracellular calcium store at the base of the sperm flagellum that regulates hyperactivated motility. Biol Reprod. 2003; 68: 1590–1596.
85. Calogero AE, Gullo G, La Vignera S, et al. Myoinositol improves sperm parameters and serum reproductive hormones in patients with idiopathic infertility: a prospective double-blind randomized placebo-controlled study. Andrology. 2015; 3: 491–495.
86. Gulino FA, Leonardi E, Marilli I, et al. Effect of treatment with myo-inositol on semen parameters of patients undergoing an IVF cycle: an in vivo study. Gynecol Endocrinol. 2016; 32: 65–68.
87. Montanino Oliva M, Minutolo E, Lippa A, et al. Effect of myoinositol and antioxidants on sperm quality in men with metabolic syndrome. Int J Endocrinol. 2016; 2016: 1674950.
88. Dinkova A, Martinov D, Konova E. Efficacy of myo-inositol in the clinical management of patients with asthenozoospermia. Eur Rev Med Pharmacol Sci. 2017; 21: 62–65.
89. Walczak-Jedrzejowska R, Wolski JK, Slowikowska-Hilczer J. Role of oxidative stress and antioxidants in male fertility. Cent European J Urol. 2013; 66: 60–67.
90. Dawson EB, Harris WA, Teter MC, et al. Effect of ascorbic acid supplementation on the sperm quality of smokers. Fertil Steril. 1992; 58: 1034–1039.
91. Thérond P, Auger J, Legrand A, et al. Alpha-tocopherol in human spermatozoa and seminal plasma: relationships with motility, antioxidant enzymes and leukocytes. Mol Hum Reprod. 1996; 2: 739–744.
92. Omu AE, Fatinikun T, Mannazhath N, et al. Simultaneous determination of serum and seminal plasma alpha-tocopherol and retinol in infertile men by high-performance liquid chromatography. Andrologia. 1999; 31: 347–354.
93. Thiele JJ, Friesleben HJ, Fuchs J, et al. Ascorbic acid and urate in human seminal plasma: determination and interrelationships with chemiluminescence in washed semen. Hum Reprod. 1995; 10: 110–115.
94. Song GJ, Norkus EP, Lewis V. Relationship between seminal ascorbic acid and sperm DNA integrity in infertile men. Int J Androl. 2006; 29: 569–575.
95. Moilanen J, Hovatta O. Excretion of alpha-tocopherol into human seminal plasma after oral administration. Andrologia. 1995; 27: 133–136.
96. Kessopoulou E, Powers HJ, Sharma KK, et al. Double-blind randomized placebo cross-over controlled trial using antioxidant vitamin E to treat reactive oxygen species-associated male infertility. Fertil Steril. 1995; 64: 825–831.
97. Suleiman SA, Ali ME, Zaki ZM, et al. Lipid peroxidation and human sperm motility: protective role of vitamin E. J Androl. 1996; 17: 530–537.
98. Cyrus A, Kabir A, Goodarzi D, et al. Effect of adjuvant vitamin C after varicocele surgery on sperm quality and quantity in infertile men: a double-blind placebo-controlled clinical trial. Int Braz J Urol. 2015; 41: 230–238.
99. Rolf C, Cooper TG, Yeung CH, et al. Antioxidant treatment of patients with asthenozoospermia or moderate oligoasthenozoospermia with high-dose vitamin C and vitamin E: a randomized placebo-controlled double-blind study. Hum Reprod. 1999; 14: 1028–1033.
100. Comhaire FH, Christophe AB, Zalata AA, et al. Effects of combined conventional treatment, oral antioxidants and essential fatty acids on sperm biology in subfertile men. Prostaglandins Leukot Essent Fatty Acids. 2000; 63: 159–165.
101. Keskes-Ammar L, Feki-Chakroun N, Rebai T, et al. Sperm oxidative stress and the effect of an oral vitamin E and selenium supplement on semen quality in infertile men. Arch Androl. 2003; 49: 83–94.
102. Greco E, Iacobelli M, Rienzi L, et al. Reduction of the incidence of sperm DNA fragmentation by oral antioxidant treatment. J Androl. 2005; 26: 349–353.
103. Moslemi MK, Tavanbakhsh S. Selenium-vitamin E supplementation in infertile men: effects on semen parameters and pregnancy rate. Int J Gen Med. 2011; 4: 99–104.
104. Kelkel M, Schumacher M, Dicato M, et al. Antioxidant and anti-proliferative properties of lycopene. Free Radic Res. 2011; 45: 925–940.
105. Liang ZW, Guo KM, Dai XF, et al. Protective effect of lycopene on human spermatozoa during cryopreservation and its mechanism. Zhonghua Nan Ke Xue. 2015; 21: 521–526.
106. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr. 2000; 71(Suppl):343S–348S.
107. Hodge WG, Schachter HM, Barnes D, et al. Efficacy of omega-3 fatty acids in preventing age-related macular degeneration: a systematic review. Ophthalmology. 2006; 113: 1165–1172.
108. Safarinejad MR. Effect of omega-3 polyunsaturated fatty acid supplementation on semen profile and enzymatic antioxidant capacity of seminal plasma in infertile men with idiopathic oligoasthenoteratozoospermia: a double-blind, placebo-controlled randomized study. Andrologia. 2011; 43: 38–47.
109. De Flora S, Cesarone CF, Balansky RM, et al. Chemopreventive properties and mechanisms of N-acetylcysteine: the experimental background. J Cell Biochem Suppl. 1995; 22: 33–41.
110. Gressier B, Cabanis A, Lebegue S, et al. Decrease of hypochlorous acid and hydroxyl radical generated by stimulated human neutrophils: comparison in vitro of some thiol-containing drugs. Methods Find Exp Clin Pharmacol. 1994;16:9–13.
111. Oeda T, Henkel R, Ohmori H, Schill WB. Scavenging effect of N-acetyl-L-cysteine against reactive oxygen species in human semen: a possible therapeutic modality for male factor infertility? Andrologia. 1997; 29: 125–131.
112. Erkkila K, Hirvonen V, Wuokko E, et al. N-acetyl-L-cysteine inhibits apoptosis in human male germ cells in vitro. J Clin Endocrinol Metab. 1998; 83: 2523–2531.
113. Ciftci H, Verit A, Savas M, et al. Effects of N-acetylcysteine on semen parameters and oxidative/antioxidant status. Urology. 2009; 74: 73–76.
114. Safarinejad MR, Safarinejad S. Efficacy of selenium and/or N-acetyl-cysteine for improving semen parameters in infertile men: a double-blind, placebo-controlled randomized study. J Urol. 2009; 181: 741–751.
115. Ahsan U, Kamran Z, Raza I, et al. Role of selenium in male reproduction: a review. Anim Reprod Sci. 2014; 146: 55–62.
116. Noack-Füller G, De Beer C, Seibert H. Cadmium, lead, selenium, and zinc in semen of occupationally unexposed men. Andrologia. 1993; 25: 7–12.
117. Chia SE, Ong CN, Chua LH, et al. Comparison of zinc concentrations in blood and seminal plasma and the various sperm parameters between fertile and infertile men. J Androl. 2000; 21: 53–57.
118. Zago MP, Oteiza PI. The antioxidant properties of zinc: interactions with iron and antioxidants. Free Radic Biol Med. 2001; 31: 266–274.
119. Colagar AH, Marzony ET, Chaichi MJ. Zinc levels in seminal plasma are associated with sperm quality in fertile and infertile men. Nutr Res. 2009; 29: 82–88.
120. Hartoma TR, Nahoul K, Netter A. Zinc, plasma androgens and male sterility. Lancet. 1977; 2: 1125–1126.
121. Tikkiwal M, Ajmera RL, Mathur NK. Effect of zinc administration on seminal zinc and fertility of oligospermic males. Indian J Physiol Pharmacol. 1987; 31: 30–34.
122. Sommer F, Bäckhed F. The gut microbiota—masters of host development and physiology. Nat Rev Microbiol. 2013; 11: 227–238.
123. Baker JM, Al-Nakkash L, Herbst-Kralovetz MM. Estrogen-gut microbiome axis: physiological and clinical implications. Maturitas. 2017; 103: 45–53.
124. Maretti C, Cavallini G. The association of a probiotic with a prebiotic to improve sperm quality and quantity in infertile patients with idiopathic oligoasthenoteratozoospermia: a pilot study. Andrology. 2017; 5: 439–444.
125. George AJ. The anabolic steroids and peptide hormones. In: Mottram DR, editor. Drugs in sport. 2nd ed. London: E & FN Spon; 1996. p. 173–218.
126. Greenblatt RB, Chaddha JS, Teran AZ, et al. Aphrodisiacs. In: Iverson SD, editor. Psychopharmacology: recent advances and future prospects. Oxford: Oxford University Press; 1985. p. 290–302.
127. Lombardo JA, Hickson PC, Lamb DR. Anabolic/androgenic steroids and growth hormone. In: Lamb DR, Williams MH, editors. Perspectives in exercise science and sports medicine. Vol 4: Ergogenics. New York: Brown and Benchmark; 1991. p. 249–278.
128. Goldman B. Death in the locker room: steroids and sport. London: Century Publishing; 1984.
129. Pope HG, Katz DL. Psychiatric and medical effects of anabolic-androgenic steroid use. Arch Gen Psychiatry. 1994; 51: 375–382.
130. Tang T, Glanville J, Orsi N, Barth JH, Balen AH. The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod. 2006; 21: 1416–1425.
131. Palomba S, Pasquali R, Orio F Jr, Nestler JE. Clomiphene citrate, metformin or both as first-step approach in treating anovulatory infertility in patients with PCOS: a systematic review and meta-analysis. Clin Endocrinol (Oxf). 2009; 70: 311–321.
132. Heard MJ, Pierce A, Carson SA, Buster JE. Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome. Fertil Steril. 2002; 77: 669–673.
133. Biagetti B, Simò R. Molecular pathways in prolactinomas: translational and therapeutic implications. Int J Mol Sci. 2021; 22: 11247.
134. Pellicer N, Galliano D, Herraiz S, et al. Use of dopamine agonists to target angiogenesis in women with endometriosis. Hum Reprod. 2021; 36: 850–858.
135. Marshburn PB, Kutteh WH. The role of antisperm antibodies in infertility. Fertil Steril. 1994; 61: 799–811.
136. Abshagen K, Behre HM, Cooper TG, Nieschlag E. Influence of sperm surface antibodies on spontaneous pregnancy rates. Fertil Steril. 1998; 70: 355–356.
137. Kamischke A, Nieschlag E. Analysis of medical treatment of male infertility. Hum Reprod. 1999; 14(Suppl 1): 1–23.
138. Wolff H. The biologic significance of white blood cells in semen. Fertil Steril. 1995; 63: 1143–1157.
139. Fedder J, Askjaer SA, Hjort T. Nonspermatozoal cells in semen: relationship to other semen parameters and fertility status. Arch Androl. 1993; 31: 95–103.
140. Curi SM, Ariagno JI, Chenlo PH, et al. Asthenozoospermia: analysis of a large population. Arch Androl. 2003; 49: 343–349.
141. Lackner JE, Herwig R, Schmidbauer J, et al. Correlation of leukocytospermia with clinical infection and the positive effect of anti-inflammatory treatment on semen quality. Fertil Steril. 2006; 86: 601–605.
142. Gallegos G, Ramos B, Santiso R, et al. Sperm DNA fragmentation in infertile men with genitourinary infection by Chlamydia trachomatis and Mycoplasma. Fertil Steril. 2008; 90: 328–334.
143. Ding L, Yan G, Wang B, Xu L, Gu Y. Stem cell therapy for ovarian aging: opportunities and challenges. Front Cell Dev Biol. 2021; 9: 650158.
144. Komaroff AL. The microbiome and reproductive health. N Engl J Med. 2022; 387: 451–460.